Cure8 research brief
The paper reports a preclinical targeted-delivery formulation that may allow lower systemic exposure to tofacitinib while concentrating drug in inflamed colon tissue—potentially reducing known systemic risks of JAK inhibitors.
Researchers, clinicians focused on IBD therapeutics, and patients interested in advances that could lower medication side effects.
This Science Advances abstract describes a lab-developed oral liposomal delivery system (Lipo-tm-HA) designed to concentrate the JAK inhibitor tofacitinib in inflamed colon tissue while reducing systemic exposure.
In mouse colitis experiments reported in the abstract, a single oral dose of the targeted formulation at 10 mg/kg showed greater efficacy than daily free tofacitinib; the authors propose improved stability in gastric conditions, mucosal adherence, and enhanced macrophage uptake as mechanisms.
Findings come from preclinical models described in the article abstract; human safety and effectiveness are not established.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases, award R01DK135269; National Institute of Biomedical Imaging and Bioengineering, award R01EB017742
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A natural compound (diosgenin) reduced disease signs and inflammatory markers in a mouse model of ulcerative colitis, suggesting a possible anti-inflammatory mechanism that could inform future preclinical research.
This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...
Researchers are testing whether short-term dual therapy with vedolizumab plus tofacitinib can induce remission in people with moderate–severe UC who have failed prior TNF blockers. If effective and safe, this approach...
